PDL1 expression is an independent prognostic factor in localized GIST

OncoImmunology

Volumn 4, Issue 5, 2015, Pages

  Bertucci, François ^a,b,c   Finetti, Pascal ^a   Mamessier, Emilie ^a   Pantaleo, Maria Abbondanza ^d   Astolfi, Annalisa ^e   Ostrowski, Jerzy ^f   Birnbaum, Daniel ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c French Sarcoma Group   (France)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

DNA microarray; Gene expression; GIST; Immune response; PDL1; Prognosis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD97 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR6; CXCL9 CHEMOKINE; PROGRAMMED DEATH 1 LIGAND 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DNA MICROARRAY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION RATE; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

EID: 84944463725     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2014.1002729     Document Type: Article

References (66)

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11:865-78; PMID:22089421
2. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; Suppl 3:iii21-6
3. Kitamura Y, Hirota S, Nishida T. Gastrointestinal stromal tumors (GIST): a model for molecule; PU1-based diagnosis and treatment of solid tumors. Cancer Sci 2003; 94:315-20; PMID:12824897; http://dx.doi.org/ 10.1111/j.1349-7006.2003.tb01439.x
4. Joensuu H, Dematteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 2011; 63:247-58; PMID:22017446; http://dx. doi.org/10.1146/annurev-med-043010-091813
5. Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011; 223:251-61; PMID:21125679; http://dx.doi.org/10.1002/path.2798
6. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11:942-9; PMID:20864406; http://dx.doi.org/10.1016/S1470-2045(10)70222-9
7. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:1097-104; PMID:19303137; http://dx.doi.org/10.1016/S0140-6736(09)60500-6
8. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307:1265-1272; PMID:22453568
9. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70-83; PMID: 17193820; http://dx.doi.org/10.1053/j.semdp. 2006.09.001
10. Gold JS, Gonen M, Gutierrez A, Broto JM, Garcia-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10:1045-52; PMID:19793678; http:// dx.doi.org/10.1016/S1470-2045(09)70242-6
11. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011; 35:1646-56; PMID:21997685; http://dx.doi.org/10.1097/PAS.0b013e31822d63a7
12. Patel S. Navigating risk stratification systems for the management of patients with GIST. Ann Surg Oncol 2011; 18:1698-704; PMID:21213058; http://dx.doi. org/10.1245/s10434-010-1496-z
13. Wozniak A, Rutkowski P, Schoffski P, Ray-Coquard I, Hostein I, Schildhaus HU, Le Cesne A, Bylina E, Limon J, Blay JY, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST. Clin Cancer Res 2014; 20(23):6105-16; PMID:25294914; http://dx.doi.org/ 10.1158/1078-0432.CCR-14-1677
14. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.1038/nm.2438
15. Cameron S, Haller F, Dudas J, Moriconi F, Gunawan B, Armbrust T, Langer C, Fuzesi L, Ramadori G. Immune cells in primary gastrointestinal stromal tumors. Eur J Gastroenterol Hepatol 2008; 20:327-34; PMID:18334877; http://dx.doi.org/10.1097/MEG. 0b013e3282f3a403
16. Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013; 73:3499-510; PMID:23592754; http://dx.doi.org/10.1158/0008-5472.CAN-13-0371
17. van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH, Hogendoorn PC, van der Burg SH, Gelderblom H, van Hall T. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 2010; 127:899-909; PMID:20013807
18. Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taieb J, Delahaye NF, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009; 69:3563-9; PMID:19351841; http://dx.doi. org/10.1158/0008-5472.CAN-08-3807
19. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366
20. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/ nrclinonc.2010.223
21. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114:379-88; PMID:15286804; http://dx.doi.org/ 10.1172/JCI21102
22. Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Translational Med 2011; 3:111ra20; http://dx.doi.org/10.1126/ scitranslmed.3003130
23. Blank C, Mackensen A. Contribution of the PD-L1/ PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother: CII 2007; 56:739-45; http://dx.doi.org/10.1007/s00262-006-0272-1
24. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206:3015-29; PMID:20008522; http://dx.doi.org/ 10.1084/jem.20090847
25. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014; 23(12):2965-70; PMID:25392179; http://dx.doi.org/10.1158/1055-9965.EPI-14-0654
26. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7; PMID:12218188; http://dx.doi. org/10.1073/pnas.192461099
27. Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy 2014; 6:459-75; PMID:24815784; http://dx. doi.org/10.2217/imt.14.9
28. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/ 10.1038/nrc3239
29. Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID: 24498550; http://dx.doi.org/10.4161/onci.26621
30. Eggermont AM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. Eur J Cancer 2013; 49:2965-7; PMID:23890942; http://dx.doi.org/ 10.1016/j.ejca.2013.06.019
31. Robert C, Soria JC, Eggermont AM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer 2013; 49:2968-71; PMID:23907003; http://dx.doi. org/10.1016/j.ejca.2013.07.001
32. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi.org/ 10.4161/onci.21335
33. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi. org/10.1056/NEJMoa1200694
34. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
35. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20: 5064-74; PMID:24714771; http://dx.doi.org/ 10.1158/1078-0432.CCR-13-3271
36. Palmer C, Diehn M, Alizadeh AA, Brown PO. Celltype specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics 2006; 7:115; PMID:16704732; http://dx.doi.org/10.1186/ 1471-2164-7-115
37. Sabatier R, Finetti P, Mamessier E, Raynaud S, Cervera N, Lambaudie E, Jacquemier J, Viens P, Birnbaum D, Bertucci F. Kinome expression profiling and prognosis of basal breast cancers. Mol Cancer 2011; 10:86; PMID:21777462; http://dx.doi.org/10.1186/1476-4598-10-86
38. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A 2010; 107:6994-9; PMID:20335537; http://dx.doi.org/ 10.1073/pnas.0912708107
39. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94:107-16; PMID:24217091; http://dx.doi.org/ 10.1038/labinvest.2013.130
40. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011; 117:2192-201; PMID:21523733; http://dx. doi.org/10.1002/cncr.25747
41. Rimm D, Schalper K, Pusztai L. Unvalidated antibodies and misleading results. Breast Cancer Res Treat 2014; 147:457-8; PMID:25086631; http://dx.doi.org/ 10.1007/s10549-014-3061-0
42. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014; 20:2773-82; PMID:24647569; http://dx. doi.org/10.1158/1078-0432.CCR-13-2702
43. Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014; 9:e88557; PMID:24551119; http:// dx.doi.org/10.1371/journal.pone.0088557
44. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer immunology research 2014; 2:690-8; PMID:24866169; http://dx.doi.org/10.1158/ 2326-6066.CIR-13-0224
45. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49:2233-42; PMID:23478000; http:// dx.doi.org/10.1016/j.ejca.2013.02.015
46. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1:54-63; PMID:24416729; http://dx.doi.org/10.1158/2326-6066.CIR-13-0034
47. Ricci R, Arena V, Castri F, Martini M, Maggiano N, Murazio M, Pacelli F, Potenza AE, Vecchio FM, Larocca LM. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 2004; 122:35-43; PMID:15272528; http://dx.doi.org/ 10.1309/MJ4XN2M57HNC8X5H
48. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, Yamada T, Nawata H, Tsuneyoshi M. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005; 36:828-37; PMID:16084954; http://dx.doi.org/ 10.1016/j.humpath.2005.03.012
49. Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, et al. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2009; 15:4191-8; PMID:19509155; http://dx.doi.org/10.1158/1078-0432.CCR-08-3297
50. Sabah M, Cummins R, Leader M, Kay E. Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications. Hum Pathol 2006; 37:648-55; PMID:16733203; http://dx.doi.org/10.1016/j. humpath.2006.01.023
51. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, Terracciano L, Pross M, Insabato L, Di Vizio D, et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005; 11:638-45; PMID:15701851
52. Bertucci F, Finetti P, Ostrowski J, Kim WK, Kim H, Pantaleo MA, Astolfi A, Polkowski M, Birnbaum D. Genomic Grade Index predicts postoperative clinical outcome of GIST. Br J Cancer 2012; 107:1433-41; PMID:22929880; http://dx.doi.org/ 10.1038/bjc.2012.390
53. Lagarde P, Perot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R, Schoffski P, et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2011; 18(3):826-38; PMID:22167411
54. Perez DR, Baser RE, Cavnar MJ, Balachandran VP, Antonescu CR, Tap WD, Strong VE, Brennan MF, Coit DG, Singer S, et al. Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor. Ann Surg Oncol 2013; 20:593-9; PMID:23054118; http://dx.doi.org/10.1245/s10434-012-2682-y
55. Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008; 8:57; PMID:18294387; http://dx.doi.org/10.1186/1471-2407-8-57
56. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Translational Med 2013; 5:200ra116; http://dx.doi.org/10.1126/ scitranslmed.3006504
57. Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu A, Saponara M, et al. A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest 2010; 90:1285-94; PMID:20548289; http://dx.doi.org/ 10.1038/labinvest.2010.110
58. Ostrowski J, Polkowski M, Paziewska A, Skrzypczak M, Goryca K, Rubel T, Kokoszynska K, Rutkowski P, Nowecki ZI, Vel Dobosz AJ, et al. Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression. BMC Cancer 2009; 9:413; PMID:19943934; http://dx.doi.org/10.1186/ 1471-2407-9-413
59. Yamaguchi U, Nakayama R, Honda K, Ichikawa H, Hasegawa T, Shitashige M, Ono M, Shoji A, Sakuma T, Kuwabara H, et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 2008; 26:4100-8; PMID:18757323; http://dx.doi.org/ 10.1200/JCO.2007.14.2331
60. Lee EJ, Kang G, Kang SW, Jang KT, Lee J, Park JO, Park CK, Sohn TS, Kim S, Kim KM. GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors. PLoS One 2013; 8:e77219; PMID:24124608; http://dx.doi.org/10.1371/journal.pone.0077219
61. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-64; PMID:12925520; http://dx.doi.org/10.1093/ biostatistics/4.2.249
62. Bertucci F, Finetti P, Viens P, Birnbaum D. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer letters 2014; 355:70-5; PMID:25218596; http://dx.doi.org/10.1016/j.canlet.2014.09.014
63. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8:118-27; PMID:16632515; http://dx.doi.org/10.1093/ biostatistics/kxj037
64. Taminau J, Steenhoff D, Coletta A, Meganck S, Lazar C, de Schaetzen V, Duque R, Molter C, Bersini H, Nowe A, et al. inSilicoDb: an R/Bioconductor package for accessing human Affymetrix expertcurated datasets from GEO. Bioinformatics 2011; 27:3204-5; PMID:21937664; http://dx.doi.org/ 10.1093/bioinformatics/btr529
65. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98:5116-21; PMID:11309499; http://dx.doi.org/ 10.1073/pnas.091062498
66. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23:9067-72; PMID:16172462; http://dx.doi.org/ 10.1200/JCO.2004.01.0454